A drug that has been used to treat parasites in animals could be an effective treatment for humans cancer. However, turning research findings into an approved medication is a long journey. According to the results of the study, fenbendazole, which is a type of antiparasitic drug, inhibited tumour growth in mice and reduced the number of lung metastases after local tumor irradiation.

Researchers conducted focus group interviews with six lung cancer patients who have used fenbendazole for their illness. The interviewees were aged between 60 and 70 years and they were interviewed by a researcher who had experience with various focus groups for cancer patients.

The interviewees were asked to describe how they acquire information on fenbendazole and general cancer information daily. They were also asked what they thought of the quality of the obtained information. The interviews were held between December 7 and 8, 2020.

SNU-C5 and SNU-C5/5-FUR colorectal cancer (CRC) cells were treated with varying concentrations of fenbendazole. Cell viability was measured using MTT assays after 3 days of treatment. The results showed that fenbendazole significantly inhibited the proliferation of both CRC cell lines. In addition, the cytotoxic effects of fenbendazole were found to be dependent on its concentration. Moreover, fenbendazole increased the expression of p53 and p21 in SNU-C5 and SNU-C5/5-FUR CRC cells and induced G2/M arrest and apoptosis through p53-p21 pathways. Furthermore, the benzimidazole is known to bind beta-tubulin and disrupt microtubules to cause cell cycle arrest. In addition, fenbendazole induces cell death in both SNU-C5 and SNU-C5/5-FUR cells through apoptosis, autophagy, and ferroptosis. fenbendazole for humans cancer